Value of systematic genetic screening of patients with amyotrophic lateral sclerosis
The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis is uncertain. Our aim was to determine whether routine targeted sequencing of 44 ALS-relevant genes would have a significant impact on clinical care and disease subclassification. We performed targeted sequencing of...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021
|
| _version_ | 1826290341093834752 |
|---|---|
| author | Shepheard, SR Parker, MD Cooper-Knock, J Verber, NS Tuddenham, L Heath, PR Beauchamp, N Place, E Sollars, ESA Project MinE ALS Sequencing Consortium Turner, M Malaspina, A Fratta, P Hewamadduma, C Jenkins, TM McDermott, CJ Wang, D Kirby, J Shaw, PJ |
| author_facet | Shepheard, SR Parker, MD Cooper-Knock, J Verber, NS Tuddenham, L Heath, PR Beauchamp, N Place, E Sollars, ESA Project MinE ALS Sequencing Consortium Turner, M Malaspina, A Fratta, P Hewamadduma, C Jenkins, TM McDermott, CJ Wang, D Kirby, J Shaw, PJ |
| author_sort | Shepheard, SR |
| collection | OXFORD |
| description | The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis is uncertain. Our
aim was to determine whether routine targeted sequencing of 44 ALS-relevant genes would have a
significant impact on clinical care and disease subclassification. We performed targeted
sequencing of a 44 gene panel in a prospective case series of 100 consecutive ALS patients
recruited sequentially from the Sheffield Motor Neuron Disorders Clinic, United Kingdom. All
participants were diagnosed with ALS by a specialist Consultant Neurologist. 7/100 patients had
familial ALS, but the majority were apparently sporadic cases.
21% of ALS patients carried a confirmed pathogenic or likely-pathogenic mutation, of whom 93%
had no family history of ALS. 15% met the inclusion criteria for a current ALS genetic-therapy trial.
5/21 patients with a pathogenic mutation had an additional variant of uncertain significance (VUS).
An additional 21% of ALS patients carried a VUS in an ALS-associated gene. Overall, 13% of
patients carried more than one genetic variant (pathogenic or VUS). ALS patients carrying two
variants developed disease at a significantly earlier age compared to patients with a single variant
(median age of onset = 56 versus 60 years, p=0.0074).
In conclusion, routine screening for ALS-associated pathogenic mutations in a specialised ALS
referral clinic will impact clinical care in 21% of cases. An additional 21% of patients have variants
in the ALS gene panel currently of unconfirmed significance after removing non-specific or
predicted benign variants. Overall, variants within known ALS-linked genes are of potential clinical
importance in 42% of patients. |
| first_indexed | 2024-03-07T02:42:42Z |
| format | Journal article |
| id | oxford-uuid:aafe2e5d-5b28-4898-bfd8-e5a993dbb0ea |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:42:42Z |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:aafe2e5d-5b28-4898-bfd8-e5a993dbb0ea2022-03-27T03:18:59ZValue of systematic genetic screening of patients with amyotrophic lateral sclerosisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:aafe2e5d-5b28-4898-bfd8-e5a993dbb0eaEnglishSymplectic ElementsBMJ Publishing Group2021Shepheard, SRParker, MDCooper-Knock, JVerber, NSTuddenham, LHeath, PRBeauchamp, NPlace, ESollars, ESAProject MinE ALS Sequencing ConsortiumTurner, MMalaspina, AFratta, PHewamadduma, CJenkins, TMMcDermott, CJWang, DKirby, JShaw, PJThe clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis is uncertain. Our aim was to determine whether routine targeted sequencing of 44 ALS-relevant genes would have a significant impact on clinical care and disease subclassification. We performed targeted sequencing of a 44 gene panel in a prospective case series of 100 consecutive ALS patients recruited sequentially from the Sheffield Motor Neuron Disorders Clinic, United Kingdom. All participants were diagnosed with ALS by a specialist Consultant Neurologist. 7/100 patients had familial ALS, but the majority were apparently sporadic cases. 21% of ALS patients carried a confirmed pathogenic or likely-pathogenic mutation, of whom 93% had no family history of ALS. 15% met the inclusion criteria for a current ALS genetic-therapy trial. 5/21 patients with a pathogenic mutation had an additional variant of uncertain significance (VUS). An additional 21% of ALS patients carried a VUS in an ALS-associated gene. Overall, 13% of patients carried more than one genetic variant (pathogenic or VUS). ALS patients carrying two variants developed disease at a significantly earlier age compared to patients with a single variant (median age of onset = 56 versus 60 years, p=0.0074). In conclusion, routine screening for ALS-associated pathogenic mutations in a specialised ALS referral clinic will impact clinical care in 21% of cases. An additional 21% of patients have variants in the ALS gene panel currently of unconfirmed significance after removing non-specific or predicted benign variants. Overall, variants within known ALS-linked genes are of potential clinical importance in 42% of patients. |
| spellingShingle | Shepheard, SR Parker, MD Cooper-Knock, J Verber, NS Tuddenham, L Heath, PR Beauchamp, N Place, E Sollars, ESA Project MinE ALS Sequencing Consortium Turner, M Malaspina, A Fratta, P Hewamadduma, C Jenkins, TM McDermott, CJ Wang, D Kirby, J Shaw, PJ Value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
| title | Value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
| title_full | Value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
| title_fullStr | Value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
| title_full_unstemmed | Value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
| title_short | Value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
| title_sort | value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
| work_keys_str_mv | AT shepheardsr valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT parkermd valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT cooperknockj valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT verberns valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT tuddenhaml valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT heathpr valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT beauchampn valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT placee valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT sollarsesa valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT projectminealssequencingconsortium valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT turnerm valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT malaspinaa valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT frattap valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT hewamaddumac valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT jenkinstm valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT mcdermottcj valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT wangd valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT kirbyj valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis AT shawpj valueofsystematicgeneticscreeningofpatientswithamyotrophiclateralsclerosis |